Trophoblastic Neoplasms

CHESTER, N.J., March 10, 2025 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a 2025 Pinnacle Life Member for her contributions to the field of Gynecologic Oncology. Continue Reading Nana E. Tchabo, MD, FACOG, Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience and a minor in Women's Studies. She then attended the Warren Alpert Brown University School of Medicine, where she was cited for academic excellence. The doctor completed a residency in Obstetrics and Gynecology at Georgetown University; a research fellowship in ovarian cancer and molecular techniques at the National Cancer Institute; and a Fellowship in Gynecologic Oncology at Roswell Park Cancer Institute in Buffalo. Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health System Morristown and Overlook Medical Centers. As part of her responsibilities, the doctor coordinates unified, comprehensive care integrating various treatments including minimally invasive surgery; chemotherapy; radiation therapy; along with supportive care services. Focused on prevention and survivorship, Dr. Tchabo is a Principal Investigator on many of the gynecologic cancer clinical research trials available at the Carol G. Simon Cancer Center and serves as Associate Residency Director for Gynecology at Overlook Medical Center. She is also an Assistant Clinical Professor at Sidney Kimmel Medical College of Thomas Jefferson University. Her prior appointments include Assistant Clinical Professor at Mount Sinai School of Medicines' Department of Obstetrics, Gynecology, and Reproductive Science. Board-certified in both Obstetrics and Gynecology & Gynecologic Oncology by the American Board of Obstetrics and Gynecology (ABOG), Dr. Tchabo notes that the mission of the ABOG is to define specialty standards; certify obstetricians and gynecologists; and facilitate continuous learning to advance knowledge; practice; and professionalism in women's health. She explained that gynecologic oncology is a specialized field of medicine that focuses on cancers of the female reproductive system, including ovarian cancer; uterine cancer; vaginal cancer; cervical cancer; vulvar cancer; gestational trophoblastic disease, and preinvasive conditions. A Gynecologic Oncologist, like Dr. Tchabo, is a physician who specializes in treating women with reproductive tract cancers. They are initially trained as Obstetrician/Gynecologists and then undergo three to possibly more than five years of specialized education in all the effective forms of treatment for gynecologic cancers (surgery; radiation; chemotherapy; immunotherapy; and clinical research trials) as well as the biology and pathology of gynecologic cancers. Dedicated to her local community, Dr. Tchabo is a member of Delta Sigma Theta Sorority, Inc. and Jack & Jill of America, Inc.. She is engaged in community service initiatives and fosters leadership skills in African-American youth. Dr. Tchabo has received many accolades during her career including Exceptional Women In Medicine: 2019, 2020, 2021, 2022, 2023; Jerseys Best Magazine Top Doctors: 2019, 2020, 2021, 2022; Jerseys Best Top Doctors for Cancer: 2019, 2021, 2022; Top Doctors New York Metro Area (digital guide): 2018, 2019, 2020, 2021, 2022; New York Magazine: Top Doctors: 2021, 2022; and Jerseys Best Top Doctors for Women's Health: 2021, 2022, and New Jersey Monthly Top Doctors: 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023,2024. She would like to dedicate this honor to her parents: Jean-Gilles Tchabo, MD and Elizabeth Anne Robertson-Tchabo, PhD. The doctor has been married to Charles desBordes, Ph.D. for 18 years and they have 2 sons. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

CHESTER, N.J., July 1, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Nana E. Tchabo, MD, FACOG, is acknowledged as a Pinnacle Life Member for her contributions to the field of Gynecologic Oncology. Continue Reading Nana E, Tchabo, MD, FACOG Dr. Tchabo pursued higher education at Brown University where she received a Bachelor of Science in Neuroscience and a minor in Women's Studies. She then attended the Warren Alpert Brown University School of Medicine, where she was cited for academic excellence. The doctor completed a residency in Obstetrics and Gynecology at Georgetown University; a research fellowship in ovarian cancer and molecular techniques at the National Cancer Institute; and a Fellowship in Gynecologic Oncology at Roswell Park Cancer Institute in Buffalo. Dr. Tchabo currently works at Atlantic Women's Cancer Associates, a part of Atlantic Health System Morristown and Overlook Medical Centers. As part of her responsibilities, the doctor coordinates unified, comprehensive care integrating various treatments including minimally invasive surgery; chemotherapy; radiation therapy; along with supportive care services. Focused on prevention and survivorship, Dr. Tchabo is a Principal Investigator on many of the gynecologic cancer clinical research trials available at the Carol G. Simon Cancer Center and serves as Associate Residency Director for Gynecology at Overlook Medical Center. She is also an Assistant Clinical Professor at Sidney Kimmel Medical College of Thomas Jefferson University. Her prior appointments include Assistant Clinical Professor at Mount Sinai School of Medicines' Department of Obstetrics, Gynecology, and Reproductive Science. Board-certified in both Obstetrics and Gynecology & Gynecologic Oncology by the American Board of Obstetrics and Gynecology (ABOG), Dr. Tchabo notes that the mission of the ABOG is to define specialty standards; certify obstetricians and gynecologists; and facilitate continuous learning to advance knowledge; practice; and professionalism in women's health. She explained that gynecologic oncology is a specialized field of medicine that focuses on cancers of the female reproductive system, including ovarian cancer; uterine cancer; vaginal cancer; cervical cancer; vulvar cancer; gestational trophoblastic disease, and preinvasive conditions. A Gynecologic Oncologist, like Dr. Tchabo, is a physician who specializes in treating women with reproductive tract cancers. They are initially trained as Obstetrician/Gynecologists and then undergo three to possibly more than five years of specialized education in all the effective forms of treatment for gynecologic cancers (surgery; radiation; chemotherapy; immunotherapy; and clinical research trials) as well as the biology and pathology of gynecologic cancers. Dedicated to her local community, Dr. Tchabo is a member of Delta Sigma Theta Sorority, Inc. and Jack & Jill of America, Inc.. She is engaged in community service initiatives and fosters leadership skills in African-American youth. Dr. Tchabo has received many accolades during her career including Exceptional Women In Medicine: 2019, 2020, 2021, 2022, 2023; Jerseys Best Magazine Top Doctors: 2019, 2020, 2021, 2022; Jerseys Best Top Doctors for Cancer: 2019, 2021, 2022; Top Doctors New York Metro Area (digital guide): 2018, 2019, 2020, 2021, 2022; New York Magazine: Top Doctors: 2021, 2022; and Jerseys Best Top Doctors for Women's Health: 2021, 2022, and New Jersey Monthly Top Doctors: 2015, 2016, 2017, 2018, 2019, 2020, 2021, 2022, 2023. She would like to dedicate this honor to her parents: Jean-Gilles Tchabo, MD and Elizabeth Anne Robertson-Tchabo, PhD. The doctor has been married to Charles desBordes, Ph.D. for 17 years and they have 2 sons. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle

Researchers have designed a new genetic therapy that could alleviate debilitating giant moles in a rare skin condition. Researchers at the Francis Crick Institute, UCL Great Ormond Street Institute for Child Health and Great Ormond Street Hospital for Children (GOSH) have designed a new genetic therapy that could alleviate debilitating giant moles in a rare skin condition. In the future, the treatment could potentially be used to reverse the giant moles, and therefore reduce the risk of affected children and adults from developing cancer. It could also potentially reverse other more common types of at-risk moles as an alternative to surgery. Small skin moles are common in the population, but in congenital melanocytic naevus syndrome (CMN), children are born with up to 80% of their body covered in big, painful or itchy moles, caused by mutations acquired in the womb. These moles can sometimes develop into a severe type of cancer called melanoma. Published today in the Journal of Investigate Dermatology, the researchers silenced a gene called NRAS, which is mutated in the cells in these moles, in cells in a dish and in mice. NRAS belongs to a group of genes (RAS genes) that, when mutated, can cause moles, and can predispose to cancer. The team used a genetic therapy called silencing RNA, which silences the mutated NRAS in mole skin cells. The therapy was delivered in special particles directly to mole cells. They gave injections containing the therapy to mice with CMN, which reduced the silenced the NRAS gene after just 48 hours. They also tested it in cells and whole skin sections from children with CMN. Silencing the gene triggered the mole cells to self-destruct. Veronica Kinsler, Principal Group Leader of the Mosaicism and Precision Medicine Laboratory at the Crick, Professor of Paediatric Dermatology and Dermatogenetics at GOSH/UCL, and NIHR Research Professor, said: "CMN is physically and mentally challenging for children and adults living with this condition and for their families. These results are very exciting, as not only does the genetic therapy trigger self-destruction of the mole cells in the lab, but we have managed to deliver it into the skin in mice. This results suggest that the treatment in future could potentially reverse moles in people, however more testing will be needed before we can give it to patients. "We are very grateful to our patients at Great Ormond Street Hospital, who have been actively participating over many years to help us produce this new potential therapy. After more studies, we hope the therapy can soon enter clinical trials in people." This research was funded by the National Institute for Health and Care Research (NIHR), Caring Matters Now Charity and Patient Support Group, LifeArc and the NIHR Great Ormond Street Hospital Biomedical Research Centre. Jodi Whitehouse, CEO of Caring Matters Now, who helped to fund the research, said: "This breakthrough in finding a treatment for CMN could transform the lives of the families we support living with CMN. As someone who was born with CMN covering 70% of my body and having undergone 30+ operations in my childhood to try and remove the CMN because of the fear of melanoma, with no success, this news is awe-inspiring and exciting. It brings real hope to the lives of those living with CMN." Catriona Crombie, Head of Rare Disease at LifeArc, said: "This work is part of our commitment to improving the lives of people living with rare diseases, by investing in promising research and helping scientists to overcome translational research barriers. If successful, we hope to see human clinical trials for this therapy within the next few years." The researchers have been working closely with the Crick's Translation team to develop the technology towards patient benefit. This has included securing translational funds from LifeArc, to carry out more research in mice to understand how the treatment works over a longer period.